Nirogacestat Dihydrobromide Crystal Forms for Solubility and Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing crystalline forms of Nirogacestat dihydrobromide, particularly Form A, exhibit low solubility and stability issues, affecting drug performance and quality during manufacturing and storage.
Innovation Solution
Development of novel crystalline forms, Form CSV and Form CSVI, with improved solubility, compressibility, and stability, achieved through specific preparation methods involving solvent systems and controlled crystallization processes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If Form A crystalline structure is used, then stability is improved, but solubility deteriorates
Solution Approach 1:
The patent applies parameter changes by discovering and characterizing multiple distinct crystalline forms (Form A, Form B, Form C, and their hydrates) of Compound I dihydrobromide, each with different solubility and stability parameters. This allows selection of the optimal crystalline form based on the specific therapeutic and manufacturing requirements, resolving the contradiction between stability and solubility through parameter variation rather than chemical modification.
2Reliability
If multiple crystalline forms are developed, then drug performance is improved, but manufacturing complexity increases
Solution Approach 1:
The patent segments the single compound into multiple distinct crystalline forms, each with optimized properties for specific applications. By characterizing and defining separate forms (anhydrates and hydrates with different crystal structures), the patent enables selective use of each form for different manufacturing scenarios, improving overall drug performance while providing clear guidelines for form selection to manage manufacturing complexity.
3Quantity of substance
If crystalline form optimization is pursued, then solubility is improved, but purification difficulty increases
Solution Approach 1:
The patent uses solvent systems as intermediaries to achieve controlled crystallization of specific forms. By selecting appropriate solvents and crystallization conditions, the patent enables selective formation of desired crystalline forms with improved solubility while maintaining ease of purification through standard crystallization techniques, thus resolving the contradiction between solubility enhancement and purification difficulty.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Form CSV and Form CSVI demonstrate enhanced solubility, compressibility, and stability, ensuring consistent drug quality and bioavailability, reducing the risk of polymorphic transitions and quality fluctuations during storage and processing.
Implementation Method 1
the X-ray powder diffraction pattern of Form CSV comprises characteristic peaks at 2theta values of 6.1°±0.2°, 9.6°±0.2° and 13.6°±0.2° using CuKα radiation
Implementation Method 2
Dissolving Compound I dihydrobromide in a mixed solvent of an ether and an acid, evaporating to obtain a solid
Implementation Method 3
heating the obtained solid to get Form CSV
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Novel crystalline forms of Nirogacestat dihydrobromide and preparation methods thereof, pharmaceutical compositions containing the crystalline forms, and uses of the crystalline forms for preparing γ-secretase inhibitor drugs and drugs for treating desmoid tumors.